Biogen BIIB reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.99, which beat the Zacks Consensus Estimate of $1.61. Earnings declined 42% year over year. Total revenues during the ...

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results , but sales fell by 7.1% year on year to $2.28 billion. Its ...

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share ...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Friday before market open. Here’s what investors should know. Biogen beat analysts’ revenue expectations by 8.6% last quarter, ...

Biogen Inc. (NASDAQ:BIIB) has outlined a 2026 profit outlook that comes in above Wall Street expectations, suggesting that aggressive cost discipline could be helping soften the impact from ongoing ...

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on Biogen Inc. (NASDAQ:BIIB) to $142 from $143 on August 1, keeping a Neutral ...

Members of Congress have traded $BIIB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales. Here’s a breakdown of recent ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid for ...

Members of Congress have traded $BIIB stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales. Here’s a breakdown of recent ...